Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV-Reference-Cited by-同舟云学术

Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV

Published:2022-01 Issue:1 Volume:59 Page:106492
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Armenia Daniele,Santoro Maria Mercedes^ORCID,Bellocchi Maria Concetta,Carioti Luca^ORCID,Galli Laura^ORCID,Galli Andrea,Scutari Rossana,Salsi Eleonora,Mussini Cristina,Sterrantino Gaetana^ORCID,Calza Leonardo,Rossetti Barbara,Zazzi Maurizio,Castagna Antonella

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference54 articles.

1. Antiretroviral Therapy: Treatment-experienced Individuals;Calvo;Infect Dis Clin North Am,2014

2. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry;Galli;Open Forum Infect Dis,2020

3. Sociodemographic, ecological, and spatiotemporal factors associated with HIV drug resistance in Florida: a retrospective analysis;Rich;J Infect Dis,2020

4. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel;Günthard;Clin Infect Dis,2019

5. Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA;Liao;Bioorg Med Chem Lett,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry;Journal of Antimicrobial Chemotherapy;2024-07-15

2. Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors;BMJ Open;2024-02

3. Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals;Journal of Clinical Virology;2023-11

4. Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial;Journal of Antimicrobial Chemotherapy;2023-11-01

5. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry;International Journal of Antimicrobial Agents;2023-03